Replies to post #30749 on PharmaCyte Biotech Inc (PMCB)

[$Pistol Pete$]

Check out the news today

http://client.irwebkit.com/Nuvilex/news/2434100

This preclinical study will be conducted by Translational Drug Development (TD2) in the United States. Pancreatic cancer expert Dr. Daniel D. Von Hoff is the Chief Development Officer of TD2 and a principal architect of the study. It is expected that the study will begin in approximately two weeks.

[Peacefulwendy]

Today's PR tells you directly that he is not only involved but the architect of the study.

This preclinical study will be conducted by Translational Drug Development (TD2) in the United States. Pancreatic cancer expert Dr. Daniel D. Von Hoff is the Chief Development Officer of TD2 and a principal architect of the study. It is expected that the study will begin in approximately two weeks.


http://finance.yahoo.com/news/pharmacyte-biotechs-expanded-study-malignant-140000166.html